Skip to content
10-K

Annual Report

LARIMAR THERAPEUTICS, INC. LRMR

0001193125-26-115878

← back to feed
Filed
Mar 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 17, 2026 103.88M sh
Capex FY 2025 · Dec 31, 2025 $91K
Capex FY 2025 · Dec 31, 2024 $515K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$113.2M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$70.76M
Cash And Equivalents FY 2025 · Dec 31, 2025 $85.41M
Cash And Equivalents FY 2025 · Dec 31, 2024 $33.22M
Stockholders Equity FY 2025 · Dec 31, 2025 $78.09M
Stockholders Equity FY 2025 · Dec 31, 2024 $171.81M
Stockholders Equity FY 2025 · Dec 31, 2023 $81.72M
Current Liabilities FY 2025 · Dec 31, 2025 $64.8M
Current Liabilities FY 2025 · Dec 31, 2024 $24.36M
Total Liabilities FY 2025 · Dec 31, 2025 $67.76M
Total Liabilities FY 2025 · Dec 31, 2024 $28.41M
Current Assets FY 2025 · Dec 31, 2025 $142.02M
Current Assets FY 2025 · Dec 31, 2024 $195.3M
Total Assets FY 2025 · Dec 31, 2025 $145.84M
Total Assets FY 2025 · Dec 31, 2024 $200.23M
Sga Expense FY 2025 · Dec 31, 2025 $18.27M
Sga Expense FY 2025 · Dec 31, 2024 $17.61M
Rd Expense FY 2025 · Dec 31, 2025 $154.22M
Rd Expense FY 2025 · Dec 31, 2024 $73.28M
Net Income FY 2025 · Dec 31, 2025 −$165.67M
Net Income FY 2025 · Dec 31, 2024 −$80.6M
Operating Income FY 2025 · Dec 31, 2025 −$172.5M
Operating Income FY 2025 · Dec 31, 2024 −$90.89M